Open report — full analysis, no account required.
Sign up to generate reports and read filings that aren't on the open list.
Get notified when MNPR files again. Create a free account and we'll email you the moment its next filing is analyzed.
Get filing alertsMonopar Therapeutics reports Q1 2026 financial results
Filed May 14, 2026 · Period ending May 14, 2026 · ~1 min read
Key Changes
-
medium
Company issued press release announcing first quarter 2026 financial results for period ended March 31, 2026. Specific financial figures not included in 8-K filing itself.
Item 2.02 verify on EDGAR → -
medium
Full financial details available in attached press release (Exhibit 99.1). Investors should review the press release for actual revenue, expenses, and cash position data.
Exhibit 99.1 view on EDGAR →
Summary
Monopar Therapeutics filed an 8-K to announce its first quarter 2026 financial results through a press release dated May 14, 2026. This is a routine quarterly disclosure required for public companies. The 8-K itself does not contain the actual financial figures—those details are in the attached press release.
Retail investors should review the full press release (Exhibit 99.1) to understand the company's cash burn rate, research and development spending, and runway. As a clinical-stage biotech, Monopar's quarterly results typically focus on operating expenses and cash position rather than revenue. Watch for any updates on clinical trial progress or partnership announcements that may have been included in the press release but not summarized in this procedural filing.
Section-by-Section Diff
Event · Item 2.02 — Results of Operations and Financial Condition
Monopar announced Q1 2026 financial results via press release on May 14, 2026.
Added in current filing · verify on EDGAR →
On May 14, 2026, Monopar Therapeutics Inc. ("Monopar" or the “Company”) issued a press release announcing its financial results for the first quarter ended March 31, 2026.
The company disclosed its first quarter 2026 financial results through a press release. The 8-K itself does not contain the actual financial figures, only references the press release as Exhibit 99.1.
Event · Item 9.01 — Financial Statements and Exhibits
Monopar Therapeutics filed an 8-K attaching a press release dated May 14, 2026; no material business event disclosed in the filing body.
Added in current filing · verify on EDGAR →
Exhibit No. | Description | 99.1 | Press Release Dated May 14, 2026
The 8-K attaches a press release dated May 14, 2026 as Exhibit 99.1. The filing body does not disclose the content or subject matter of the press release, so the nature of the announcement cannot be determined from this 8-K alone.
Thanks — your feedback helps us improve report quality.
Figures/quotes linked to EDGAR · Narrative written by AI · Jun 1, 2026 · How we verify